Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific…

Boehringer Ingelheim and Cue Biopharma Forge Strategic Partnership to Advance Targeted Autoimmune Therapy

Boehringer Ingelheim and Cue Biopharma Forge Strategic Partnership to Advance Targeted Autoimmune Therapy (IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to engage virus-specific T cells and target B…

Boehringer and Cue to develop autoimmune disease therapies

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

Boehringer Ingelheim and Cue Biopharma Partner to Develop Next-Generation Treatment for Autoimmune and Inflammatory Diseases

Boehringer Ingelheim and Cue Biopharma, Inc. announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. [Boehringer Ingelheim] Press Release

Boehringer's bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M

Plus, news about MetaVia, NAYA Biosciences, Spruce Biosciences and Orion: Boehringer Ingelheim licenses bispecific for autoimmune diseases: The private pharma company will pay Cue Biopharma $12 million upfront ...

Age-Associated B Cells in Autoimmune Diseases: Pathogenesis and Clinical Implications

As a heterogeneous B cell subset, age-associated B cells (ABCs) exhibit distinct transcription profiles, extrafollicular differentiation processes, and mul